Leukemia & Lymphoma
Volume 61, 2020 - Issue 12
Open access
5,749
Views
11
CrossRef citations to date
0
Altmetric
Original Articles
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy
David Strausa Memorial Sloan Kettering Cancer Center, New York City, NY, USACorrespondence[email protected]
View further author information
, View further author information
Graham Collinsb Oxford Cancer and Hematology Center, Churchill Hospital, Oxford, UKView further author information
, Jan Walewskic Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, PolandView further author information
, Pier Luigi Zinzanid Institute of Hematology Seragnoli, University of Bologna, Bologna, ItalyView further author information
, Andrew Grigge Department of Clinical Haematology, Austin Hospital, Melbourne, AustraliaView further author information
, Anna Suredaf Institut Català d'Oncologia-Hospitalet, Hospital Quirón Dexeus, Barcelona, SpainView further author information
, Arpad Illesg University of Debrecen, Faculty of Medicine, Debrecen, HungaryView further author information
, Tae Min Kimh Seoul National University Hospital, Seoul, Republic of KoreaView further author information
, Sergey Alekseevi Petrov Research Institute of Oncology, St. Petersburg, RussiaView further author information
, Lena Spechtj Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
, Valeria Buccherik Hematology Service, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, BrazilView further author information
, Anas Younesa Memorial Sloan Kettering Cancer Center, New York City, NY, USAView further author information
, Joseph Connorsl BC Cancer Centre for Lymphoid Cancer, Vancouver, CanadaView further author information
, Andres Forero-Torresm Seattle Genetics, Bothell, WA, USAView further author information
, Keenan Fentonm Seattle Genetics, Bothell, WA, USAView further author information
, Ashish Gautamn Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
, Indra Purevjaln Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
, Rachael Liun Millennium Pharmaceuticals, Cambridge, MA, USAhttps://orcid.org/0000-0001-6033-4510View further author information
& Andrea Gallaminio Research and Clinical Innovation, Antoine-Lacassagne Cancer Center, Nice, FranceView further author information
show all
Pages 2931-2938
|
Received 06 Mar 2020, Accepted 29 Jun 2020, Published online: 25 Aug 2020
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.